$556.8 Million
21.3%
North America
2022-2030
The demand for artificial pancreas devices has increased lately as the cases related to pancreatic ailments and failures have grown substantially. The market is set to attain revenues valued at USD 341.08 million while forging ahead at a CAGR of 21.10% in the upcoming forecast period between 2017 and 2023. The escalating number of cases being diagnosed with diabetes is the key factor in promoting the development of the market. The rising inflow of investment in the market is expected to improve the product quality, thus increasing the sales of the market. As patients these days are more or less aware of the treatment options, they are also increasingly involved in the selection of their treatment options in certain cases. This factor is anticipated to reflect positively in the expansion of the artificial pancreas device system market in the upcoming forecast period.
Report Overview
The market perspective offered by MRFR spans the entire market and gives in-depth coverage of the latest trends that are shaping the future of the artificial pancreas device system market. The report aptly captures the development of the market through current market trends, historical growth analysis, and revenue projections for a period ranging to 2023. The market also mentions CTR (Control to Range) Systems and CTT (Control to Target) Systems. The end user segments such as hospital and medical centers are also significantly emphasized upon, and a detailed analysis of the segments is also presented in the report. The market dynamics related to pricing and feasibility analysis is significantly along with macroeconomic indicators, and feasibility indicators provides a comprehensive overview of the artificial pancreas device system market in the forecast period.
Report Coverage
The report on the artificial pancreas device system market consists of market dynamics, forecast, historical market trends, market value by region as well as by country-level analysis for each market segment, segmentation, market factor analysis and key player’s market share analysis that includes supply chain and Porter’s five forces analysis of the market.
Companies Covered
Medtronic Plc, Bigfoot Biomedical, Johnson & Johnson, Dexcom Inc., Cellnovo, Tandem Diabetes Care Inc., Pancreum Inc., TypeZero Technologies LLC, Beta Bionics, F. Hoffmann-La Roche Ltd, Inreda Diabetic B.V., Insulet Corp
Research Methodology
The progression of research while creating reports at Market Research Future includes highlights and facts that are essential to the expansion of artificial pancreas device system market. The research initiated by our analysts enhances the capability of our clients to outline their vision for growth better. The unification of primary and secondary research approaches in our reports divulges widespread information connected to new revenue pockets and developing markets globally. The report methodology also ensures strategy roadmaps that exhibit a distinct picture of the present trends as well as the trends that can affect the forthcoming development of the artificial pancreas device system market. An intrinsic level of understanding connected to the value chain in a specific market additionally contributes to the value of the reports created by our analysts. Furthermore, the insights into markets, technologies, and industry sectors is positively achieved by the application of top-down and bottom-up approaches.
Segmental Analysis
The segmentation of the artificial pancreas device market has been carried out to better gauge the artificial pancreas device system market.
By Type
By End User
By Region
Report Attribute/Metric | Details |
---|---|
Market Size | 2023: 341.08 million |
CAGR | 2018-2023: 21.10% |
Base Year | 2019 |
Forecast Period | 2027 |
Historical Data | 2018 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Type, End User and Region |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Medtronic Plc, Bigfoot Biomedical, Johnson & Johnson, Dexcom Inc., Cellnovo, Tandem Diabetes Care Inc., Pancreum Inc., TypeZero Technologies LLC, Beta Bionics, F. Hoffmann-La Roche Ltd, Inreda Diabetic B.V., Insulet Corp |
Key Market Opportunities | Product Manufacturer |
Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
The types are included in the artificial pancreas device system market are CTR (Control to Range) Systems, CTT (Control To Target) Systems.
The major drivers of artificial pancreas device system market are Medtronic Plc, Bigfoot Biomedical, Johnson & Johnson, Dexcom Inc., Cellnovo, Tandem Diabetes Care Inc., Pancreum Inc., TypeZero Technologies LLC, Beta Bionics, F. Hoffmann-La Roche Ltd, Inreda Diabetic B.V., Insulet Corp.
Artificial Pancreas Device System Market is expected to reach US 341.08 million and at a CAGR 21.10% through 2023.
The Major driving factor of Artificial Pancreas Device System Market is Number of cases being diagnosed with diabetes.